Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

Condition:   Metastatic HPV-16 Positive Squamous Cell Anal Cancer Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Drug: Pembrolizumab (KEYTRUDA(R));   Biological: Individual Patient TCR-Transduced PBL Sponsor:   National Cancer Institute (NCI) Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials